bergamot reduces plasma lipids, atherogenic small dense ldl, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months prospective study
Clicks: 720
ID: 178635
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
80.8
/100
720 views
537 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #1 of 333 articles by views in chemical research in chinese universities
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Some patients experience statin-induced side effects or prefer nutraceutical approaches for the treatment of dyslipidemia. This has led to a search for alternative therapeutic approaches for dyslipidemia management. In recent studies Citrus bergamia (known as Bergamot) juice was able to reduce serum levels of lipids. Such benefit may be attributed to high amounts of flavonoids contained in Bergamot fruit juice (neoeriocitrin, neohesperidin, naringin). The aim of the present study was to fully investigate the effects of a Bergamot extract on cardio-metabolic parameters, including plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis. Methods: Eighty subjects (42 men and 38 women, mean age: 55±13 years) with moderate hypercholesterolemia (e.g., with plasma LDL-cholesterol concentrations between 160 and 190 mg/dl [between 4.1 and 4.9 mmol/l]) were included. A Bergamot-derived extract (Bergavit®) was given at a fixed dose daily (150 mg of flavonoids, with 16% of neoeriocitrin, 47% of neohesperidin and 37% of naringin) for 6 months. Lipoprotein subfractions were assessed by gel electrophoresis. With this methodology low density lipoprotein (LDL) subclasses are distributed as seven bands (LDL-1 and -2 as large LDL, and LDL-3 to -7 as atherogenic small, dense LDL). Subclinical atherosclerosis was assessed by carotid intima-media thickness (cIMT) using B-mode ultrasound. Results: After 6 months, Bergavit® reduced total cholesterol (from 6.6±0.4 to 5.8±1.1 mmol/l, p<0.0001), triglycerides (from 1.8±0.6 to 1.5±0.9 mmol/l, p=0.0020), and LDL-cholesterol (from 4.6±0.2 to 3.7±1.0 mmol/l, p<0.0001), while HDL- cholesterol increased (from 1.3±0.2 to 1.4±0.4 mmol/l, p<0.0007). In addition, a significant increase in LDL-1 (from 41.2±0.2 to 49.6±0.2 %, p<0.0001) was accompanied by decreased small, dense LDL-3, -4 and 5 particles (from 14.5±0.1% to 9.0±0.1% p<0.0001; 3.2±0.1% to 1.5±0.1% p=0.0053; 0.3±0.0% to 0.1±0.0 % p=0.0133, respectively). cIMT also decreased from 1.2±0.4 to 0.9±0.1 mm (p<0.0001). Conclusion: This is the first study investigating the effects of Bergamot flavonoids supplementation on cardio-metabolic risk in dyslipidemic subjects. Bergavit® (Bergamot juice extract) supplementation significantly reduced plasma lipids and improved the lipoprotein profile. cIMT was also reduced significantly over a relatively short time frame of 6 months.
| Reference Key |
etoth2016frontiersbergamot
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Peter P. eToth;Peter P. eToth;Angelo Maria ePatti;Dragana eNikolic;Rosaria Vincenza eGiglio;Giuseppa eCastellino;Teresa eBiancucci;Fabiana eGeraci;Fabiana eGeraci;Sabrina eDavid;Giuseppe eMontalto;Ali eRizvi;Manfredi eRizzo;Manfredi eRizzo;Manfredi eRizzo |
| Journal | chemical research in chinese universities |
| Year | 2016 |
| DOI |
10.3389/fphar.2015.00299
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.